INDV Stock Overview Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Indivior Historical stock prices Current Share Price UK£9.46 52 Week High UK£17.70 52 Week Low UK£5.55 Beta 0.27 1 Month Change 22.95% 3 Month Change 29.08% 1 Year Change -19.74% 3 Year Change -27.44% 5 Year Change 380.07% Change since IPO 26.07%
Recent News & Updates Indivior PLC Announces Ryan Preblick Steps Down as Chief Financial Officer
Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment Nov 20
A Piece Of The Puzzle Missing From Indivior PLC's (LON:INDV) 35% Share Price Climb Nov 15
Jerome Lande to Step Down from the Board of Indivior plc Nov 15
Oaktree Capital Sends a Letter to Indivior PLC Nov 07
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 24 See more updates Indivior PLC Announces Ryan Preblick Steps Down as Chief Financial Officer
Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment Nov 20
A Piece Of The Puzzle Missing From Indivior PLC's (LON:INDV) 35% Share Price Climb Nov 15
Jerome Lande to Step Down from the Board of Indivior plc Nov 15
Oaktree Capital Sends a Letter to Indivior PLC Nov 07
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 24 Indivior PLC Revises Financial Guidance for the Fiscal Year 2024
Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review Oct 07
Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board Oct 04
Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump Sep 24
Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder Sep 04
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration Aug 27
Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story Aug 09
Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers Aug 03
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 28 Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million. Jul 27
Consensus EPS estimates increase by 44% Jul 26
Consensus EPS estimates fall by 37% Jul 10
Indivior PLC Revises Financial Guidance for the Fiscal Year 2024 Jul 10 Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024 Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)
Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression Jun 19
Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder Jun 13
Indivior PLC's (LON:INDV) Shares Not Telling The Full Story May 29
Indivior plc Reaffirms Revenue Guidance for the Year 2024 May 25
Indivior PLC Announces Board Committee Changes May 11
Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why May 03
Indivior plc Reconfirms Earnings Guidance for 2024 Apr 27
First quarter 2024 earnings: EPS and revenues miss analyst expectations Apr 25
We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt Apr 10
Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024 Mar 22 Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024
CEO & Executive Director recently sold UK£1.5m worth of stock Mar 20
Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone Mar 12
Chief Human Resources Officer recently sold UK£1.8m worth of stock Mar 08
The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More Feb 28
Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022) Feb 23
Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024 Jan 20
Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%? Dec 11
Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million. Nov 18
Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023 Nov 11
New major risk - Financial position Nov 10
Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022) Nov 10
Indivior PLC Announces Executive Changes Nov 09
Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023 Oct 24
We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt Oct 15
Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023 Oct 06
Two Seas Capital Provides Information to Shareholders of Indivior PLC Oct 05
Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023 Oct 01
Indivior PLC Revises Earnings Guidance for the Year 2023 Jul 29
Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022) Jul 28
Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023 Jun 29
Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023 Jun 28
We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt Jun 27
Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl May 23
Chief Manufacturing & Supply Officer recently sold UK£1.7m worth of stock May 12
Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet Mar 29
Full year 2022 earnings: EPS misses analyst expectations Mar 28
Full year 2022 earnings: Revenues in line with analyst expectations Feb 17
Indivior PLC Announces Board and Committee Changes Feb 17
Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023 Jan 12
Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022 Dec 07
Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly Nov 24
High number of new directors Nov 16
Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million. Nov 16
Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million. Nov 15
Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021) Oct 27
Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims Oct 25
Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022 Oct 05
Indivior PLC, Annual General Meeting, Sep 30, 2022 Sep 07
Indivior PLC, Annual General Meeting, Sep 30, 2022 Sep 06
Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S Aug 26
Indivior PLC Provides Revenue Guidance for the Full Year Jul 30
Indivior plc Announces Executive Changes Jul 29
Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021) Jul 28
Indivior (LON:INDV) Seems To Use Debt Quite Sensibly Jul 26
Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022 Jul 08
Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film Jun 25
Indivior Names Nina DeLorenzo Chief Global Impact Officer Jun 17
Investor sentiment deteriorated over the past week Jun 14
Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder Jun 02
First quarter 2022 earnings: EPS and revenues exceed analyst expectations Apr 29
Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022 Apr 28
High number of new directors Apr 27
Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC Apr 26
Indivior PLC Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users Apr 09 Shareholder Returns INDV GB Pharmaceuticals GB Market 7D 5.4% -0.9% -1.4% 1Y -19.7% -0.6% 4.6%
See full shareholder returns
Return vs Market: INDV underperformed the UK Market which returned 4.6% over the past year.
Price Volatility Is INDV's price volatile compared to industry and market? INDV volatility INDV Average Weekly Movement 8.3% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.3% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: INDV's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: INDV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
Show more Indivior PLC Fundamentals Summary How do Indivior's earnings and revenue compare to its market cap? INDV fundamental statistics Market cap UK£1.19b Earnings (TTM ) -UK£2.36m Revenue (TTM ) UK£931.20m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) INDV income statement (TTM ) Revenue US$1.18b Cost of Revenue US$208.00m Gross Profit US$974.00m Other Expenses US$977.00m Earnings -US$3.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.024 Gross Margin 82.40% Net Profit Margin -0.25% Debt/Equity Ratio -142.5%
How did INDV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 21:46 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Indivior PLC is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Graham Glyn Parry BofA Global Research Brian White Cantor Fitzgerald Europe Chase Knickerbocker Craig-Hallum Capital Group LLC
Show 14 more analysts 
